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bjectives We investigated attenuated plaque (hypoechoic plaque with deep ultrasonic attenuation
espite absence of bright calcium) in nonculprit lesions.
ackground Recent intravascular ultrasound (IVUS) studies describe acoustic shadowing behind
arge, echolucent, acute culprit lesion sites in the absence of bright calcium. Such “attenuated
laque” is considered a characteristic of high-risk lesions, but its prevalence in stable nonculprit le-
ions is incompletely known.
ethods We reviewed IVUS pullback data from nonculprit vessels in 159 patients from the ASTEROID
A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma
urden) trial. We identiﬁed attenuated plaque and compared volumetric IVUS data in the segments with
nd without attenuation. In addition, we described plaque morphology in segments with attenuation at
aseline and follow-up.
esults Attenuated plaque was found in 17 of 159 patients (10.7%, 95% conﬁdence interval: 6% to
7%). At baseline, there were no signiﬁcant differences in clinical presentation and cardiovascular
isk factors between patients with and without attenuation. Other than a greater plaque eccentricity
ndex (p  0.008), there were no signiﬁcant differences between segments with and without attenu-
tion. In segments with attenuated plaque, expansive remodeling was observed in 53%, and calci-
ed plaque adjacent to the attenuation site in 70% of patients. During follow-up, attenuation re-
ained stable, and no events occurred in the patients with attenuation.
onclusions Attenuated plaque is present in a signiﬁcant number of nonculprit segments in pa-
ients enrolled in IVUS progression trials and remains stable during follow-up. There is a relationship
ith mixed calciﬁed lesions. These ﬁndings challenge the prior assumption that attenuated plaque is
ﬁnding limited to culprit lesions associated with acute clinical presentation. (J Am Coll Cardiol
ntv 2009;2:672–8) © 2009 by the American College of Cardiology Foundation
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673ntravascular ultrasound (IVUS) allows limited character-
zation of atherosclerotic plaque morphology based on the
chogenicity of the reflected signal. Accepted categories
nclude echolucent, echodense, and echodense with shad-
wing (“calcified”) plaque and reflect underlying plaque
omposition (1). Acoustic shadowing describes areas of
ignal void behind highly reflective or absorbent structures
nd is typically seen behind calcified plaque. However, very
ense fibrous plaques may also produce sufficient attenua-
ion to cause acoustic shadowing (1).
Recent observations at culprit lesions in patients with
cute coronary syndromes have described acoustic shadow-
ng behind large, echolucent plaques (Fig. 1). This finding
as been termed “attenuated plaque” and has been consid-
red an IVUS characteristic of high-risk lesions (2–4). The
oncept that attenuated plaque is an exclusive marker of
esion instability is supported by recent data showing ab-
ence of attenuation at the lesion sites causing stable
oronary syndromes (5), and could have therapeutic impli-
ations in the setting of percutaneous coronary intervention
4). However, to understand the significance of “attenua-
ion,” it is important to investigate its presence and fre-
uency in stable, nonculprit lesion sites.
We hypothesized that attenuated plaque can be present in
essel segments unrelated to clinical presentation. To test
his hypothesis, we systematically evaluated the presence of
ttenuated plaque at nonculprit lesion sites in patients
nrolled in an atherosclerosis progression trial.
ethods
ubject selection. We examined IVUS data from the AS-
EROID (A Study to Evaluate the Effect of Rosuvastatin
n Intravascular Ultrasound-Derived Coronary Atheroma
urden) trial (6). Similar to other IVUS progression trials,
nly patients with at least 1 obstructive lesion were included,
nd IVUS was performed in a vessel not containing the
ulprit lesion. Because attenuated plaque is typically de-
cribed in larger plaques, we selected 159 patients with
ercent atheroma volume above the median for this study.
tandard IVUS acquisition and analysis data derived from the
STEROID trial data. The acquisition protocol in the AS-
EROID trial has been described in detail previously (6).
n brief, after anticoagulation and administration of intra-
oronary nitroglycerin, a high-frequency ultrasound imag-
ng catheter (40 MHz) was inserted in a nonculprit target
essel as far distally as possible. Continuous ultrasonic
maging was acquired during withdrawal of the catheter
hrough the segment of artery at a constant rate of 0.5
m/s. Images were stored on videotape and subsequently
igitized for analysis in a single core laboratory by individ-
als who were blinded to the clinical characteristics and
reatment status of the patients. sImages spaced precisely 1 mm apart in the segment of
nterest were selected for analysis. Using the National
nstitutes of Health Image public domain software (version
.62, National Institutes of Health, Bethesda, Maryland),
anual planimetry was used to trace the leading edge of the
uminal and the external elastic membrane (EEM) borders.
he EEM area, lumen area, minimal plaque thickness,
aximal plaque thickness, maximal luminal diameter, and
inimal luminal diameter were measured. The plaque area
defined as: EEM area – lumen area), percentage cross-
ectional area reduction (defined as: plaque area/EEM area
100%), and plaque eccentricity index (defined as: plaque
nd media thickness maximum/plaque and media thickness
in 2.0) were calculated. Total atheroma volume was
alculated as the average of the differences between EEM
nd lumen areas across all evaluable slices and then normal-
zed to the length corresponding to the median numbers of
omparable slices in the whole population. Percentage
theroma volume, representing the proportion of the vessel
olume occupied by atheroma, was calculated as the per-
entage of the sum of EEM areas occupied by total
theroma volume.
Calcification was identified as
righter echoes than adventitia
ith acoustic shadowing. The ex-
ent of calcification was described
y the percentage of images con-
aining calcium. The atheroma
rea was not calculated for images
ontaining calcium with an acous-
ic shadow 90° that precluded
ccurate planimetry of the EEM
eading edge, resulting in exclusion of these images from
olume calculations.
dentiﬁcation of attenuated plaques. For the current study,
ll IVUS pullbacks were reanalyzed by 2 independent
bservers (O.B. and P.S.). Attenuated plaque was defined as
ypoechoic plaque with deep ultrasonic attenuation despite
he absence of bright calcium. Plaques with attenuation
ere included in the analysis if the 2 observers agreed. The
roups with and without attenuated plaque were compared
ith regard to clinical characteristics, overall vessel ather-
ma burden, and distribution at baseline based on the data
erived from the ASTEROID trial database.
edicated plaque analysis in segments with attenuation at
aseline. In segments with attenuated plaque at baseline,
urther analysis was performed at the cross section with
ttenuated plaque and adjacent images at 1-mm intervals,
-mm proximally and 5-mm distally.
At the cross section with attenuated plaque, the lumen,
laque, and EEM area were measured by planimetry. If the
EM area could not be identified because of attenuation,
e interpolated the EEM area. Plaque area and cross-
Abbreviations
and Acronyms
CI  confidence interval
EEM  external elastic
membrane
IVUS  intravascular
ultrasound
RI  remodeling indexectional area stenosis were calculated. Remodeling was
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674efined by calculating the ratio of the EEM area at the site
ith attenuation, compared with the EEM area at a
eference site containing the least amount of plaque in the
0-mm proximal to this site. Remodeling was categorized as
xpansive (remodeling index [RI] 1.05), none (0.95  RI
1.05) or constrictive (RI 0.95) at that site.
The distance of attenuated plaque from the respective
oronary ostia was determined by multiplying motorized
ullback speed rate (0.5 mm/s) by the time of the pullback.
For the 5-mm segments proximal and distal to the site
ith attenuation, the average EEM area, lumen area, plaque
rea, and cross-sectional area stenosis were calculated (6 for
oth proximal and distal segments). The presence of cal-
ium in the proximal and distal segments was described by
he percentage of images containing calcium.
Similar analysis was performed in matched segments at
-year follow-up.
tatistical analysis. Results are expressed as mean  SD for
ontinuous variables and tested with the Student t test or
ilcoxon test if nonparametric. Percentages are presented
or categorical variables and tested with the chi-square
tatistic. Fisher exact test was used for variables with low
xpected cell frequencies. A 95% confidence interval (CI)
round the frequency of attenuated plaque was calculated
sing exact binomial probabilities. For the comparison of
VUS measurements between the cross section with atten-
ated plaque versus the proximal and distal sections, a 1-way
nalysis of variance was used with location used as a
epeated factor. Student paired t test was used to test the
ifferences between baseline and follow-up attenuated
laque cross sections. A value of p  0.05 was considered
ignificant. All analyses were conducted using SAS statisti-
al software version 8.2 (SAS Institute, Cary, North
Figure 1. Two Examples of Plaques With Attenuation
Attenuated plaque was deﬁned as plaque with deep ultrasonic attenuation de
(B) Attenuation between 5 o’clock and 8 o’clock.arolina).esults
revalence of Attenuated Plaque
ttenuated plaque was found in 17 of 159 patients (10.7%,
5% CI: 6% to 17%) at baseline.
bsence of bright calcium. (A) Attenuation between 6 o’clock and 9 o’clock.
Table 1. Patient Characteristics at Baseline
Parameter
No Attenuated Plaque
(n  142)
Attenuated Plaque
(n  17)
p
Value
Age, yrs 58.7 9.72 59.8 10.11 0.68
Female sex 25.4 5.9 0.12*
BMI 29.6 4.8 27.9 2.8 0.15*
Diabetes 11.3 5.9 0.70
Hypertension 94.4 100 0.60
Unstable angina 10.6 11.8 1.00*
Dyslipidemia 50 52.9 0.82
History of angina 54.2 76.5 0.08
History of MI 28.9 47.1 0.13
Baseline medications
Beta-blocker 76.8 70.6 0.56*
Aspirin 93.7 100 0.60*
ACE inhibitor 48.6 41.2 0.56
Baseline parameters
Total cholesterol 206.3 41.9 213.7 28.9 0.24
LDL-C 134.1 33.1 137.7 22.8 0.32
HDL-C 43.3 10.8 45.6 10.5 0.35
TG, median [IQR] 127 [90–166] 148 [116–191] 0.17
Systolic blood pressure 132.8 20.3 135.4 21.2 0.90
Diastolic blood pressure 75.4 10.2 79.9 11.2 0.07
Results are expressed asmean SD or %, unless otherwise indicated. *Fisher exact test.
ACE  angiotensin-converting enzyme; BMI  body mass index; HDL-C  high-density li-
poprotein cholesterol; IQR  interquartile range; LDL-C  low-density lipoprotein cholesterol;spite aMImyocardial infarction; TG triglycerides.
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675omparison of Clinical and IVUS Findings in Segments
ith and Without Attenuation at Baseline
atient characteristics in patients with and without attenu-
ted plaque. The patient characteristics of each group are
ummarized in Table 1. There were no differences in terms
f age, sex, and cardiovascular risk factors between the 2
roups. There were no significant differences in clinical
resentation, with 15 patients (10.7%) in the no-attenuated
laque group and 2 patients (11.2%) in the attenuated
laque group presenting with unstable coronary syndromes.
here was a trend toward a more frequent history of angina
n the patients with attenuated plaque (76.5% vs. 54.2%;
 0.08).
VUS measurements in segments with and without attenu-
ted plaque. Volumetric IVUS findings in segments with
nd without attenuated plaque are summarized in Table 2.
he EEM volume, lumen volume, and percent and total
theroma volumes were found to be similar. However, the
ean plaque eccentricity index was significantly greater in
he attenuated plaque group (4.4 1.76 vs. 5.9 2.40, p
.008).
VUS Characteristics in Segments With
ttenuation at Baseline
he IVUS characteristics at the attenuated plaque site and
djacent segments are summarized in Table 3. Plaque
Table 2. IVUS Measurements in Segments With and Without Attenuated
Plaque From the ASTEROID Trial Baseline Data
Parameter
No Attenuated Plaque
(n  142)
Attenuated Plaque
(n  17)
p
Value
EEM volume 587.3 157.7 572.8 135.5 0.8
Lumen volume 342.7 103.1 327.2 73.0 0.9
PAV 41.6 8.0 42.3 7.7 0.6
TAV 244.6 80.8 245.6 84.8 0.7
Mean eccentricity index 4.4 1.8 5.9 2.4 0.008
% Images with calcium,
median [IQR]
32.9 [8.8, 51.4] 34.5 [29.9, 36.0] 0.85
Results are expressed as mean SD unless otherwise indicated.
ASTERIOD A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived
CoronaryAtheromaBurden; EEMexternal elasticmembrane; IVUS intravascular ultrasound; PAV
 percent atheroma volume; TAV total atheroma volume; other abbreviations as in Table 1.
Table 3. IVUS Measurements in Attenuated Plaque Segments at Baseline,
Proximal Segment Cross
EEM area 17.1 0.8
Plaque  media area 8.5 0.4
Lumen area 8.6 0.5
Average cross-sectional area stenosis 50.5 1.7
Eccentricity index 6.2 0.8
Results are expressed as least-square mean standard error. *The p value compares proximal segAttP attenuated plaque; other abbreviations as in Table 2.urden and eccentricity index were significantly higher in
ttenuated plaque cross sections. Nine of the 17 patients
53%) with attenuated plaque demonstrated expansive re-
odeling, 5 patients (29%) showed no remodeling, and 3
atients (18%) showed negative remodeling. By definition,
here was no evidence of calcification at the attenuated
laque site. However, 35.3 23.5% of slices in the proximal
egment and 19.6  34.0% of slices in the distal segment
howed evidence of calcification (p 0.001). At least 1
alcified plaque was identified somewhere within the entire
0-mm segment in 70% of patients with attenuated plaque.
hen we classified these plaques according to their local-
zation relative to the attenuated plaque site, 59% were
bserved in the proximal and 24% were observed in the
istal 5-mm segments (Fig. 2).
The mean distances from the coronary artery ostia to the
ttenuated plaque cross section were shortest in the left
nterior descending (24.4  15.9 mm), followed by left
ircumflex (29.0 21.9 mm) and then right coronary artery
34.2  26.1 mm, p  0.7).
linical and IVUS Data During 2-Year Follow-Up
uring 2-year follow-up, 1 patient in the no attenuated
laque group developed a myocardial infarction and 1
atient developed a stroke. None of the 17 patients with
ttenuated plaque developed myocardial infarction, death,
r stroke.
In these 17 patients the attenuated areas were unchanged
t follow-up (Fig. 3). However, the atheroma areas at
he sites of attenuated plaque were found smaller at the
ollow-up than at baseline. All other IVUS measurements
ere not significantly changed (Table 4).
iscussion
xamining nonculprit segments in patients enrolled in
VUS progression trials, we found attenuated plaque in
bout 11% of patients. Dedicated analysis of the site with
ttenuation demonstrated greater plaque burden and eccen-
ricity than in the adjacent segments. The adjacent segments
requently demonstrated calcification in the vicinity of
ttenuated plaques. Comparison of clinical presentation and
d on Dedicated Analysis
ion With AttP Distal Segment p Value* p Value†
9 0.8 15.9 0.8 0.87 0.38
5 0.4 8.1 0.4 0.01 0.002
8 0.5 7.8 0.5 0.03 0.18
4 1.7 51.1 1.7 0.001 0.001
9 0.8 6.3 0.8 0.03 0.03
AttP segment; †the p value compares distal segment to AttP segment.Base
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676linical characteristics in patients with and without attenu-
ted plaque, as well as IVUS characteristics in segments
ith and without attenuation, showed no significant differ-
nces at baseline. During 2-year follow-up, lesion morphol-
gy remained stable, and no acute events occurred in the
atient with attenuation.
Our results contribute to the understanding of plaque
ttenuation and its potential relationship to plaque vulner-
bility. In a previous study (4), attenuated plaque was
bserved at culprit lesions of patients presenting with acute
oronary syndromes and was found to be associated with
reater transient deterioration in coronary flow, larger in-
arct size, and higher incidence of fatal arrhythmia following
ercutaneous coronary intervention in patients with acute
Figure 2. IVUS Cross Section at the Site With Attenuation and an Adjacen
This ﬁgure shows an intravascular ultrasound (IVUS) cross section at the site w
Evidence of calciﬁcation was frequently present in the vicinity of attenuated p
Figure 3. Plaque Site With Attenuation at Baseline and 2-Year Follow-Up
This ﬁgure shows a plaque site with attenuation at baseline (A) and 2-year fol
changed.oronary syndromes. Importantly, in a recent study by Lee
t al. (5) attenuated plaque was found in 25.6% of 293
atients presenting with acute coronary syndromes, but it
as not present in 100 randomly selected patients with
table angina. Therefore, attenuation has been described as
characteristic marker of vulnerable lesions, with potential
herapeutic implications in the setting of percutaneous
oronary intervention. However, to understand the signifi-
ance of attenuation, it is important to know its presence
nd frequency at nonculprit lesion sites and the natural
istory of such lesions. The presence of attenuation at
onculprit lesions in our data, regardless of clinical presen-
ation, and the stability during follow-up challenge the
revious assumption that attenuated plaque is a finding
e With IVUS Criteria of Calcification
enuation (A) and an adjacent image with IVUS criteria of calciﬁcation (B).
.
(B). Presence of attenuation and plaque morphology is not signiﬁcantlyt Imag
ith attlow-up
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677imited to culprit lesions associated with acute clinical
resentation.
The reasons for these discrepancies are unclear. However,
t is important to consider that the presence of a plaque
haracteristic at a site remote from the culprit lesion is not
efinitive evidence refuting its association with plaque
nstability. Most notably, in literature regarding plaque
upture, investigators reported that the rupture can be
dentified distant from the lesion site, particularly in the
etting of acute presentation (7–11). Similarly, the stability
f such findings during follow-up could reflect the effect of
he pharmacologic intervention, rather than natural history
8). Furthermore, in our study, dedicated analysis of the
egments with attenuation demonstrates plaque character-
stics previously associated with plaque vulnerability. These
nclude expansive remodeling (12,13), lesion eccentricity
14,15), and the location/distribution in the coronary tree
16,17).
Intravascular ultrasound validation versus histology will
e critical. Previous pathological studies have provided
imited insight into the etiology of acoustic attenuation
18,19). In a series of 107 human cadaver coronary arteries,
amada et al. (18) demonstrated that the percentage of
brofatty and necrotic core plaque areas were significantly
reater in plaques with attenuation than those without.
dditionally, von Kossa staining indicated the presence of
icrocalcification within deep fibrotic tissue layers (19).
nother histologic study found fibrofatty tissue compo-
ents, extensive necrotic tissue containing cholesterol crys-
als, and microcalcification in close association with severe
laque calcification (20).
Taken together, these histological findings suggest that
ttenuated plaque may be related to an inhomogeneous
alcification process, with multiple reflective surfaces asso-
iated with microcalcification in fibrofatty and necrotic
issue. Particularly in large plaques with these histologic
ndings, diminished power in the far field of the ultrasound
ay cause deep ultrasonic attenuation without the charac-
eristic highly echogenic signal of more densely calcified
laque. Our finding of the frequent presence of calcification
n the images adjacent to the image with attenuation is
Table 4. IVUS Measurements at the Cross Sections With Attenuation at
Baseline and Follow-up
Baseline Follow-Up p Value
EEM area 16.9 3.2 15.3 3.3 0.2
Plaque  media area 10.15 1.89 8.7 2.0 0.04
Lumen area 6.8 2.1 6.6 2.1 0.8
Average cross-sectional area stenosis 60.4 7.2 57.5 8.3 0.3
Eccentricity index 8.9 4.2 7.6 3.3 0.3
Results are expressed as mean SD.
Abbreviations as in Table 2.onsistent with these findings, suggesting the presence of aomogeneous, mixed calcified plaque. Interestingly, such
esions have been associated with unstable lesions in both
VUS and computed tomography studies (21–23). Future
dvanced IVUS data analysis studies may provide further
nsights (22,24,25).
tudy limitations. Our study is limited by the relatively
mall number of lesions with attenuated plaque and the lack
f direct comparison of matched lesion sites with and
ithout plaque attenuation. Matching individual lesions
ased on size and morphology is impractical due to selection
ias. We, therefore, compared results of the entire vessel
egment containing attenuation to segments without atten-
ation, based on data collected in the original clinical trial.
nother limitation is based on the selection of patients with
plaque burden above the mean, which was done to ensure
omparability to previous studies. It is likely that the
revalence of attenuation in patients with a smaller plaque
urden is lower. The follow-up data is limited by the small
umber of lesions with attenuation, well-known limitations
f matching individual lesions at different time points, and
he likelihood that the pharmacological intervention caused
laque stabilization.
onclusions
ur results demonstrate attenuated plaque in a significant
ercentage of nonculprit segments in patients enrolled in
VUS progression trials and relative stability during follow-
p. The frequent presence of calcification adjacent to the
ross section with attenuated plaque confirms a relationship
ith mixed calcified lesions. These findings challenge the
revious assumption that attenuated plaque is an exclusive
nding of culprit lesions associated with acute clinical
resentation. Our data should caution against precocious
se of this finding as a basis for interventional decision
aking until more data becomes available.
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